Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR bind SHC1

Stable Identifier
R-HSA-9665416
Type
Reaction [binding]
Species
Homo sapiens
Compartment
cytosol, plasma membrane
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR bind SHC1
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

RAS signaling is activated dowsntream of ERBB2 ECD mutants ERBB2 G309A (Bose et al. 2013), ERBB2 G309E (Greulich et al. 2012) and ERBB2 S310F (Greulich et al. 2012), as evidenced by activating phosphorylation of ERKs (MAPK1 and MAPK3). It is assumed that phosphorylated heterodimers of ERBB2 ECD mutants and EGFR, like phosphorylated heterodimers of the wild type ERBB2, bind to SHC1.

Literature References
PubMed ID Title Journal Year
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Kavuri, SM, Searleman, AC, Shen, W, Shen, D, Koboldt, DC, Monsey, J, Goel, N, Aronson, AB, Li, S, Ma, CX, Ding, L, Mardis, ER, Ellis, MJ

Cancer Discov 2013
22908275 Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

Greulich, H, Kaplan, B, Mertins, P, Chen, TH, Tanaka, KE, Yun, CH, Zhang, X, Lee, SH, Cho, J, Ambrogio, L, Liao, R, Imielinski, M, Banerji, S, Berger, AH, Lawrence, MS, Zhang, J, Pho, NH, Walker, SR, Winckler, W, Getz, G, Frank, D, Hahn, WC, Eck, MJ, Mani, DR, Jaffe, JD, Carr, SA, Wong, KK, Meyerson, M

Proc. Natl. Acad. Sci. U.S.A. 2012
Participants
Input
Output
Participates
as an event of
Normal reaction
SHC1 binds phosphorylated ERBB2 heterodimers (Homo sapiens)
Functional status

Gain of function of p-6Y-ERBB2 ECD mutants:EGF:p-6Y-EGFR [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2019-10-30)
Reviewed
Bose, R  (2019-10-25)
Krishna, A  (2019-10-25)
Kancha, RK  (2019-11-03)
Created
Orlic-Milacic, M  (2019-10-30)
Cite Us!